Replies to post #326856 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Some will win, others lose.

Did that help?

Well, sure (snerk).

Plain and simple. Everyone will decide on the Anavex story based upon his or her perceptions and perspectives. For some, the story will be true only after the FDA approves an Anavex drug. For others, sufficient evidence of safety and efficacy allows and supports the taking of an early AVXL position, before FDA approval(s).

Stay away until....

Or,

For best investment results, carefully get in now.

Deliberations on the errors or misunderstandings of those with opposite views will change nothing. Until blarcamesine is allowed to be sold, there will continue to be both Anavex naysayers ("Stay away. Not enough good evidence."); and Anavex supporters ("Consider the pre-clinical evidence, which projects eventual FDA approvals.").

By the end of 2022, after at least one of the clinical trials terminates, and the FDA has approved or rejected blarcamesine, the matter will be settled. Hasten the day.

Of course, I'm so appreciative of the naysayers' postings. I've got a bit of my discretionary personal wealth tied up in my AVXL position, which I'm going to hold until it is utterly worthless, or until it appreciates by orders of magnitude. If I'm wrong in believing that blarcamesine will gain FDA sales approval and I lose my dollars, I'll fatefully ponder how I should have acted on the message board naysayings. Presently, I'm grateful for them. They keep me focused; continuing to examine the entirety of Anavex science as it continues grow and evolve.

If Anavex fails, I'm out just a bit. But what about the institutional owners of hundreds of thousands of AVXL shares? How could they be so deluded in committing large amounts of dollars to a company like Anavex? No sales. No revenues. No product they can yet sell. One would certainly think they could properly consider the multitude of Anavex naysayings, here and elsewhere. About 36% of the AVXL equities in trade are held by institutions (https://fintel.io/so/us/avxl).

[chrismiss_everyday]

At least do your due diligence before cluttering the board with obstinacy.

“Our preclinical findings for ANAVEX 3-71 demonstrate its significant potential to enhance neuroprotection and cognition via concomitant activation of sigma-1 receptor and M1 muscarinic acetylcholine receptor (M1R), which could be a therapeutic advantage in treating Alzheimer’s and other related protein-aggregation diseases,” said study author Abraham Fisher, PhD. “Specifically, the study results reveal that ANAVEX 3-71 effects a strong reversal of synaptic loss in hippocampal neurons. At very low doses, it mitigates cognitive deficits and normalizes major pathological hallmarks in Alzheimer’s disease models indicating that ANAVEX 3-71 exerts a comprehensive disease-modifying effect. This data adds to the strong foundation of preclinical evidence to support the potential use of ANAVEX 3-71 in Alzheimer’s disease and a wide array of other central nervous system diseases.”